Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;204(3):1109-1113.
doi: 10.1111/bjh.19270. Epub 2023 Dec 18.

Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost!

Gian Maria Asioli  1 , Carlo Alberto Castioni  2 , Pier Luigi Zinzani  3   4 , Maria Chiara Casadio  5 , Elisabetta Pierucci  5 , Beatrice Casadei  3   4 , Luca Spinardi  6 , Cinzia Pellegrini  3 , Massimiliano Bonafé  3   4 , Enrico Maffini  3 , Maria Guarino  1 , Pietro Cortelli  1   7 , Francesca Bonifazi  3
Affiliations

Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost!

Gian Maria Asioli et al. Br J Haematol. 2024 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest related to this paper.

References

REFERENCES

    1. Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T cell-associated neurotoxicity. Front Immunol. 2020;11:577027. https://doi.org/10.3389/fimmu.2020.577027
    1. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society for immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8:e001511. https://doi.org/10.1136/jitc-2020-001511
    1. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. https://doi.org/10.1016/j.bbmt.2018.12.758
    1. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. https://doi.org/10.1016/S1470-2045(18)30864-7
    1. Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019;86(1):42-54. https://doi.org/10.1002/ana.25502

Publication types

LinkOut - more resources